Mayer Rokitansky Kuster Hauser Syndrome
0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
City TherapeuticsMA - Cambridge
1 programQuality of Life and Sexual Function in Vaginal Aplasia Patients After Davydov ProcedureN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
City TherapeuticsQuality of Life and Sexual Function in Vaginal Aplasia Patients After Davydov Procedure
Imagine PharmaBiological samples for patients
Clinical Trials (2)
Total enrollment: 410 patients across 2 trials
NCT04923217City TherapeuticsQuality of Life and Sexual Function in Vaginal Aplasia Patients After Davydov Procedure
Quality of Life and Sexual Function in Vaginal Aplasia Patients After Davydov Procedure
Start: Dec 2021Est. completion: Nov 2022
N/ACompleted
Molecular Genetic Study of Mayer-Rokitansky-Kuster-Hauser Syndrome
Start: May 2016Est. completion: May 2031410 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 410 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.